{
    "organizations": [],
    "uuid": "47dc44074321418269b08a17a20d901c365c5b1e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-idera-pharmaceuticals-enters-into/brief-idera-pharmaceuticals-enters-into-a-clinical-development-support-agreement-with-pillar-partners-foundation-idUSFWN1RT0A2",
    "ord_in_thread": 0,
    "title": "BRIEF-Idera Pharmaceuticals Enters Into A Clinical Development Support Agreement With Pillar Partners Foundation",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16 (Reuters) - Idera Pharmaceuticals Inc:\n* IDERA PHARMACEUTICALS ENTERS INTO A CLINICAL DEVELOPMENT SUPPORT AGREEMENT WITH PILLAR PARTNERS FOUNDATION TO EXPAND THE CLINICAL RESEARCH ON IMO-2125 BEYOND PD-1 REFRACTORY MELANOMA\n* IDERA PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, PILLAR PARTNERS TO PROVIDE DIRECT FUNDING TO EXPAND CLINICAL RESEARCH OF IMO-2125 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-16T19:16:00.000+03:00",
    "crawled": "2018-04-17T12:27:56.015+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "idera",
        "pharmaceutical",
        "inc",
        "idera",
        "pharmaceutical",
        "enters",
        "clinical",
        "development",
        "support",
        "agreement",
        "pillar",
        "partner",
        "foundation",
        "expand",
        "clinical",
        "research",
        "beyond",
        "refractory",
        "melanoma",
        "idera",
        "pharmaceutical",
        "inc",
        "term",
        "agreement",
        "pillar",
        "partner",
        "provide",
        "direct",
        "funding",
        "expand",
        "clinical",
        "research",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}